Key Highlights
- MYGN closed up 31.59% at $5.54 on October 20 and is up 31.90% over the week, with a market capitalization of about $530 million.
- The stock is up 33.49% over the past month.
- Second-quarter revenue fell 11% to $190.7 million from $213.1 million.
- 2026 revenue guidance was cut to $770 million to $790 million from $860 million to $880 million.
- Cash was $115.2 million against long-term debt of $120.7 million at June 30.
Why Did Myriad Genetics Stock Jump 31.59% in One Session, and What May Investors Be Missing?
Myriad Genetics (NASDAQ:MYGN) closed up 31.59% at $5.54 on October 20 and is up 31.90% over the week, with a market capitalization of about $530 million. The one-day advance accounts for nearly all of the weekly gain, and the stock is up 33.49% over the past month. A search of company filings and news did not surface an acquisition offer, activist involvement, a preannouncement or a payer decision tied to the move, so the cause remains unconfirmed.
What may be missed is the backdrop. The latest reported quarter, ended June 30 and reported on July 30, was weak, and management cut its full-year revenue outlook. The jump therefore came without a disclosed change in fundamentals.
How Weak Was Myriad's Second Quarter?
Myriad is a molecular diagnostics company with hereditary cancer, prenatal and mental health franchises.
Revenue was $190.7 million, down 11% from $213.1 million, and tests fell 1% to 379,000. Revenue per test declined 9%, including an $11.0 million reduction from changes to prior-period collection estimates. The first-quarter report had shown revenue of $200.4 million, up 2%, so the second quarter marked a sharp deterioration in trend.
What Did the Guidance Cut and Balance Sheet Show?
Myriad reported a net loss of $43.2 million, against a $330.5 million loss a year earlier that included $316.7 million of impairments. Adjusted EBITDA was a loss of $16.9 million, compared with a profit of $14.5 million a year earlier, and GAAP gross margin was 66.6%.
Guidance was cut. Myriad lowered its 2026 revenue outlook to $770 million to $790 million from the $860 million to $880 million range it gave with first-quarter results, kept adjusted gross margin at 66% to 67% and withdrew its adjusted EBITDA guidance. Cash was $115.2 million and long-term debt was $120.7 million at June 30.
How Does Myriad Compare With Alamar Biosciences, Another Weekly Gainer?
Alamar Biosciences (NASDAQ:ALMR) also finished the week higher, up 17.87%, but on a different footing. Its second-quarter revenue rose 82% to $29.4 million and it guided to 2026 revenue of $116 million to $120 million. Alamar is the larger company by market value at about $1.95 billion against about $530 million for Myriad, even though Myriad's quarterly revenue is more than six times Alamar's.
Annualizing the second-quarter revenue figures, Myriad's market value is about 0.7 times revenue and Alamar's is about 16.6 times, a gap that reflects revenue direction: Myriad's revenue fell 11% while Alamar's rose 82%.
Will Myriad's Next Report Explain the Move and Test the Reset Guidance?
Myriad's one-day surge came after a quarter of falling revenue and a guidance reduction, and without an identified catalyst. Its next report will show whether test volumes and revenue per test have stabilized and whether revenue is tracking the reset range of $770 million to $790 million. The date of that report was not identified in the material reviewed, and any later company disclosure may clarify what prompted the October 20 move.






Please wait processing your request...